{"efta_number": "EFTA00655621", "page_count": 2, "url": "https://epstein-data.com/EFTA00655621", "pdf_url": "https://epstein-data.com/pdf/EFTA00655621.pdf", "pages": [{"efta_number": "EFTA00655621", "page_number": 0, "text_content": "Jeffrey Epstein. Science Philanthropist Supports Key Discoveries in the Late Onset of Alzheimer's. \nAlthough there is a genetic disposition for Alzheimer's Disease, the late onset of Alzheimer's and by far \nthe most common, is still a mystery. It's also expected to double by 2050. Today however, renowned \nNew York science investor, Jeffrey Epstein, whose foundation has provided funds to the American \nAlzheimer's Association, has heralded new findings into the late developing disease. \nThe findings come from researchers at Mount Sinai Hospital in New York City, the Icelandic Heart \nAssociation, Sage Bionetworks and Merck Research Laboratories, who have determined that a cluster of \ngenes connected to the brain's inflammatory response mechanism, play a role in driving late onset \nAlzheimer's. Specifically, the research team analyzed the DNA of 376 deceased patients with late \nAlzheimer's along with gene expression and the emanating biological pathways. What resulted was a \ncomparative mathematical model, a unified map of not only the prevailing genes present in late \nAlzheimer's but the various pathways that they trigger. \nOne such gene, TYROBP, not typically connected to Alzheimer's but linked to brain inflammation, was \nshown to interact with TREM2, a gene recently connected to Alzheimer's by Rita Guerreiro, University \nCollege London, and Thorlakur Jonsson, deCODE Genetics, et al. Researchers determined that the \nreoccurring TREM2-TYROBP pathway could be playing a main role in the onset of late Alzheimers. \nThe discovery is critical, explains Dr. Bin Zhang, a co-lead author of the study and Associate Professor of \nGenetics and Genomic Sciences at Mount Sinai. Because we can now \"evaluate drugs that impact the \nTREM2-TYROBP pathway as potential therapies... and design more specific compounds that target these \nkey steps precisely, in contrast to existing anti-inflammatory drugs that may be less ideal for hitting this \ntarget. \" Jun Zhu, PhD, Professor of Genetics and Genomic Sciences at Mount Sinai and also an author of \nthe study, stated \"These discoveries, provide unequivocal proof that inflammation plays a central role in \nAlzheimer's disease, which is a consistent theme among common complex diseases that also include \nobesity and type II diabetes.\" Valur Emilsson, PhD, Head of Systems Medicine at Icelandic Heart \nAssociation and also a senior author of the paper, added, \"Currently, we see a long lag time between \nappearance of amyloid on brain scans of patients and the appearance of clinical symptoms. An \nindividual's inflammatory response could well play a role in the disease progression, and an appropriate \nanti-inflammatory drug, given after amyloid is detected but before symptoms begin, could be an \nimportant part of dementia prevention.\" \n\"The use of a mathematical model to understand the genetic /.... Is pivotal in science research today,\" \nJeffrey Epstein asserted. \"One can detect patterns that are otherwise hidden.\" Indeed, Jeffrey Epstein is \nEFTA00655621\n", "char_count": 3023}, {"efta_number": "EFTA00655621", "page_number": 1, "text_content": "not new to the use of mathematics in science. In 2003, he founded the Program for Evolutionary \nDynamics, at Harvard University, the first of its kind to study the evolution of micro-biology with the use \nof mathematics. \nMr. Epstein has been a Trustee of the Institute of International Education Inc. since October 2001. He is a \nformer member of the Trilateral Commission, the Council on Foreign Relations, the New York Academy \nof Science and a former board member of Rockefeller University. Mr. Epstein is actively involved in the \nSanta Fe Institute, the Theoretical Biology Initiative at the Institute for Advanced Study in Princeton, the \nQuantum Gravity Program at the University of Pennsylvania, and also sits on the Mind, Brain & Behavior \nAdvisory Committee at Harvard University. He is an active member of The Edge Organizatin Inc. an \nonline group of award winning academics and authors in the sciences and social sciences. \nEFTA00655622\n", "char_count": 951}]}